Vernal keratoconjunctivitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:70476H16.2
Who is this for?
Show terms as
3FDA treatments1Active trials27Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Vernal keratoconjunctivitis (VKC) is a long-term, recurring inflammatory condition that affects the outer surface of the eye — specifically the conjunctiva (the clear tissue lining the eyelids and covering the white of the eye) and the cornea (the clear front surface of the eye). The name 'vernal' comes from the Latin word for spring, because symptoms often get worse during warmer months, though many people experience problems year-round. VKC is sometimes called 'spring catarrh' or 'warm-weather conjunctivitis,' though these older terms are less commonly used today. VKC is driven by an overactive immune response, similar to severe allergies. The immune system mistakenly attacks the eye's surface, causing intense inflammation. This leads to the hallmark symptoms: severe itching, thick mucus discharge, sensitivity to light, and a feeling like something is stuck in the eye. In more serious cases, the cornea can be damaged, which may affect vision. Raised, cobblestone-like bumps can form on the inside of the upper eyelid, and a white ring called a Horner-Trantas dot may appear at the edge of the cornea. Treatment focuses on controlling inflammation and protecting the eye from damage. Options include antihistamine eye drops, mast cell stabilizers, anti-inflammatory drops (including corticosteroids and cyclosporine), and in some cases, newer biologic medications. With proper management, most people can protect their vision and live comfortably, though the condition often requires ongoing care throughout childhood and adolescence.

Also known as:

Key symptoms:

Intense eye itching, often described as unbearableThick, ropy or stringy mucus discharge from the eyeSensitivity to light (photophobia)A feeling that something is stuck in the eye (foreign body sensation)Redness of the eyesExcessive tearing or watery eyesSwollen or drooping eyelidsCobblestone-like bumps on the inside of the upper eyelidBlurred visionEye pain or discomfortWhite or grayish spots at the edge of the cornea (Horner-Trantas dots)Corneal ulcers or scarring in severe casesWorsening symptoms in warm, sunny, or windy weather

Clinical phenotype terms (23)— hover any for plain English
Abnormal cornea morphologyHP:0000481Abnormal conjunctiva morphologyHP:0000502Abnormal sclera morphologyHP:0000591KeratoconjunctivitisHP:0001096Allergic conjunctivitisHP:0007879Corneal neovascularizationHP:0011496Punctate keratitisHP:0011859AllergyHP:0012393Red eyeHP:0025337Conjunctival hyperemiaHP:0030953Giant conjunctival papillaeHP:0025350Ocular pruritusHP:0033841Corneal foreign body sensationHP:0034804ScarringHP:0100699BlepharitisHP:0000498KeratoconusHP:0000563
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026SANDIMMUNE: New indication approved
FDAcompleted
Mar 2026SANDIMMUNE: New indication approved
FDAcompleted
Mar 2026A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Laboratoires Thea — PHASE2

TrialNOT YET RECRUITING
Dec 20253% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis

The University of Hong Kong — PHASE3

TrialNOT YET RECRUITING
Sep 2025Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis

Sohag University — NA

TrialNOT YET RECRUITING
Jun 2025Corneal Topography in Vernal Keratoconjunctivitis

Assiut University

TrialNOT YET RECRUITING
Mar 2025Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids

Superior University

TrialACTIVE NOT RECRUITING
Feb 2025Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis

Mohsen Pourazizi — PHASE1

TrialNOT YET RECRUITING
Sep 2023SANDIMMUNE: New indication approved
FDAcompleted
Mar 2022SANDIMMUNE: New indication approved
FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

Verkazia

cyclosporine· Harrow Eye, LLCOrphan Drug

Treatment of vernal keratoconjunctivitis (VKC) in children and adults

Alomide Ophthalmic Solution

Lodoxamide tromethamine· Alcon Laboratories, Inc.Orphan Drug

Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.

Opticrom 4% ophthalmic solution

Cromolyn sodium 4% ophthalmic solution· Fisons CorporationOrphan Drug

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids
Active
· Sites: Lahore, Punjab Province · Age: 525 yrs

Specialists

Showing 25 of 27View all specialists →
PP
Philippe Kesteleyn, MD, PhD
Specialist
PI on 1 active trial
AS
Abraham Solomon
BROOKLYN, NY
Specialist
3 Vernal keratoconjunctivitis publications
AZ
Anna Maria Zicari
Specialist
5 Vernal keratoconjunctivitis publications
DG
Daniele Giovanni Ghiglioni
Specialist
4 Vernal keratoconjunctivitis publications
GB
Giulia Brindisi
Specialist
3 Vernal keratoconjunctivitis publications
MN
Marcella Nebbioso
Specialist
3 Vernal keratoconjunctivitis publications
MR
Marie Louise Roed Rasmussen
Specialist
3 Vernal keratoconjunctivitis publications
YS
Yousif Subhi
Specialist
3 Vernal keratoconjunctivitis publications
GB
Gaia Bruschi
Specialist
2 Vernal keratoconjunctivitis publications
SO
Silvia Osnaghi
Specialist
2 Vernal keratoconjunctivitis publications
GM
Gian Luigi Marseglia
Specialist
2 Vernal keratoconjunctivitis publications
DC
DeGaulle I Chigbu
Specialist
2 Vernal keratoconjunctivitis publications
MS
Marta Sacchetti
Specialist
2 Vernal keratoconjunctivitis publications
AB
Alice Bruscolini
Specialist
2 Vernal keratoconjunctivitis publications
AL
Andrea Leonardi
Specialist
6 Vernal keratoconjunctivitis publications
AP
Andréa LEONARDI, Professor
Specialist
PI on 1 active trial1 Vernal keratoconjunctivitis publication
AM
alessandro lambiase, MD
Specialist
PI on 1 active trial1 Vernal keratoconjunctivitis publication
SM
Stefano Bonini, MD
Specialist
PI on 1 active trial
QM
Quan D Nguyen, MD, MSc
Specialist
PI on 5 active trials
SS
Samir S Shoughy
Specialist
PI on 2 active trials
CP
Christophe Baudouin, Pf.
Specialist
PI on 1 active trial
DP
David BenEzra, Pf
Specialist
PI on 1 active trial
RR
Rebecca Rebecca
Specialist
PI on 1 active trial
MG
Michele Miraglia Del Giudice
Specialist
3 Vernal keratoconjunctivitis publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Verkazia(cyclosporine)Harrow Eye, LLC

Travel Grants

No travel grants are currently matched to Vernal keratoconjunctivitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Vernal keratoconjunctivitisForum →

No community posts yet. Be the first to share your experience with Vernal keratoconjunctivitis.

Start the conversation →

Latest news about Vernal keratoconjunctivitis

No recent news articles for Vernal keratoconjunctivitis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my child's VKC, and is there any corneal damage already present?,Which eye drops do you recommend, and how do we use them safely long-term without steroid side effects?,How often should we come in for check-ups, and what signs should prompt an urgent visit?,Are there any known triggers we should try to avoid to reduce flare-ups?,Will my child's VKC likely improve as they get older, and what is the expected outlook for their vision?,Are there any newer treatments, such as biologic therapies, that might be appropriate for my child?,What should we do if symptoms suddenly get much worse or vision changes?

Common questions about Vernal keratoconjunctivitis

What is Vernal keratoconjunctivitis?

Vernal keratoconjunctivitis (VKC) is a long-term, recurring inflammatory condition that affects the outer surface of the eye — specifically the conjunctiva (the clear tissue lining the eyelids and covering the white of the eye) and the cornea (the clear front surface of the eye). The name 'vernal' comes from the Latin word for spring, because symptoms often get worse during warmer months, though many people experience problems year-round. VKC is sometimes called 'spring catarrh' or 'warm-weather conjunctivitis,' though these older terms are less commonly used today. VKC is driven by an overac

How is Vernal keratoconjunctivitis inherited?

Vernal keratoconjunctivitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Vernal keratoconjunctivitis typically begin?

Typical onset of Vernal keratoconjunctivitis is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Vernal keratoconjunctivitis?

Yes — 1 recruiting clinical trial is currently listed for Vernal keratoconjunctivitis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Vernal keratoconjunctivitis?

25 specialists and care centers treating Vernal keratoconjunctivitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Vernal keratoconjunctivitis?

4 patient support programs are currently tracked on UniteRare for Vernal keratoconjunctivitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.